Related Experiment Video

Updated: May 24, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Bcl-2 inhibitors: emerging drugs in cancer therapy

C Bodur1, H Basaga

  • 1Biological Sciences and Bioengineering Program, Sabanci University, 34956 Orhanli, Tuzla, Istanbul, Turkey.

Current Medicinal Chemistry
|March 15, 2012
PubMed

Insights

Small molecule inhibitors targeting antiapoptotic Bcl-2 proteins offer a novel cancer therapy approach. These BH3 mimetics reduce normal tissue toxicity and enhance existing treatments, potentially lowering patient drug doses.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Dose-limiting toxicity to healthy tissues and multi-drug resistance are major challenges in anticancer treatment.
  • Conventional therapies often interfere with fundamental cellular processes like DNA synthesis and mitosis, leading to significant side effects.

Purpose of the Study:

  • To review and compare small molecule inhibitors (SMIs) specific for antiapoptotic Bcl-2 proteins, known as BH3 mimetics.
  • To evaluate their specificity, mode of action, efficacy, and therapeutic potential in future anticancer strategies.

Main Methods:

  • This review summarizes existing literature on BH3 mimetics targeting antiapoptotic Bcl-2 proteins.
  • Comparison of different BH3 mimetics based on their specificity, mechanism of action, and demonstrated efficacy.

Main Results:

  • BH3 mimetics act by competing with proapoptotic Bcl-2 proteins for binding sites on antiapoptotic family members.
  • These inhibitors lower the apoptotic threshold in tumor cells, rather than directly inducing cell death, leading to reduced normal tissue toxicity.
  • Bcl-2 antagonists have shown potential in potentiating established drugs for hematological malignancies and solid tumors.

Conclusions:

  • Antiapoptotic Bcl-2 protein SMIs represent a promising therapeutic strategy with lower normal tissue toxicity compared to conventional treatments.
  • BH3 mimetics are valuable candidates for combination anticancer therapy, potentially reducing the overall drug dosage required for patients.
  • Further development and clinical investigation are warranted to fully realize the therapeutic potential of these novel agents.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...